Following a previous favorable advisory committee recommendation, US health care major Abbott Laboratories (NYSE: ABT) said yesterday that the European Commission has now approved its Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy.
With this approval, Humira becomes the first and only self-injectable biologic therapy for the treatment of moderately to severely active ulcerative colitis in adults. The approval also marks the seventh indication for Humira in the European Union since the product's first clearance in 2003.
Humira is the group’s best-selling drug and will be part of the new AbbVie that the company intends to be a split-off for its research-based drug business into a separate publicly-traded company (The Pharma Letter March 22). Humira’s global sales increased 21.1% to $7.9 billion in 2011,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze